Clinical guideline update recommends SGLT2 inhibitors to prevent hospitalization and cardiovascular death in heart failure, highlighting benefits regardless of diabetes status.
Key Points
To update the Heart Failure Association of the European Society of Cardiology position paper regarding the clinical use of SGLT2 inhibitors based on recent trial evidence.
Reviewed and integrated recent clinical trial evidence evaluating SGLT2 inhibitors in populations with heart failure and type 2 diabetes mellitus.
Formulated updated consensus practice recommendations for patient subgroups based on ejection fraction, cardiovascular risk, and diabetes status.
Canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin are recommended to prevent heart failure hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or high cardiovascular risk.
Dapagliflozin or empagliflozin are recommended to reduce the combined risk of heart failure hospitalization and cardiovascular death in symptomatic heart failure with reduced ejection fraction on guideline-directed therapy, regardless of diabetes status.